Why Compare Wegovy 1.7mg vs Mounjaro Before Maintenance?
Wegovy 1.7mg Price vs Mounjaro: The Essential Comparison
When evaluating Wegovy 1.7mg price against Mounjaro, you're comparing two distinct mechanisms of action that work differently in your body. Wegovy contains semaglutide, a GLP-1 receptor agonist, whilst Mounjaro contains tirzepatide, which targets both GLP-1 and GIP receptors—a dual approach. This fundamental difference affects not only how each medication may support your weight management goals but also their pricing structures and dosing schedules.
At this critical 1.7mg stage, you're just one dose away from Wegovy's 2.4mg maintenance level, making it an ideal time to evaluate long-term options. Our Wegovy 1.7mg price of £139.99 represents weeks 13-16 of your escalation journey, whilst Mounjaro follows a different six-dose escalation from 2.5mg to 15mg over 20 weeks. Understanding these pathways helps you and your prescriber choose the most suitable prescription-only medicine for your individual needs.
Wegovy 1.7mg Price Structure and Bundle Options
Our Wegovy 1.7mg price of £139.99 reflects the penultimate dose in your escalation schedule, with new customers applying code FIRST40 and returning customers using DOSE25 at checkout to achieve this pricing. For those planning ahead, our Elevate Duo bundle (1.7mg + 2.4mg) costs £369.99, providing a seamless transition to maintenance dosing with Reliable Supply continuity. This bundle approach offers convenience through reduced ordering frequency and consolidated cold-chain delivery.
When comparing Wegovy 1.7mg price against equivalent Mounjaro doses, consider that Mounjaro's escalation schedule differs significantly—their 7.5mg dose (roughly equivalent timing) follows different pricing due to the distinct manufacturing and supply chain requirements. Our transparent pricing structure eliminates hidden costs, with all prices including clinical assessment, prescriber review, and temperature-controlled next-day delivery through our GPhC-registered pharmacy (#9012878).
Clinical Evidence Behind Wegovy 1.7mg Price Positioning
The Wegovy 1.7mg price reflects robust clinical evidence from the STEP trial programme, where participants achieved significant weight management outcomes. In STEP 1, patients taking Wegovy alongside diet and exercise experienced approximately 15% average weight loss at 68 weeks, compared to 2.4% with placebo (Wilding et al., NEJM, 2021). This evidence supports the medication's positioning as a prescription-only medicine requiring clinical oversight.
Mounjaro's clinical profile stems from the SURMOUNT trials, demonstrating its own efficacy profile through the dual GLP-1/GIP mechanism. However, direct comparison of trial outcomes isn't appropriate due to different study designs, patient populations, and methodologies. Both medications represent evidence-based approaches to weight management, with your prescriber best positioned to evaluate which option aligns with your clinical profile and treatment goals.
Understanding How Wegovy 1.7mg Works
At the 1.7mg dose level, Wegovy's semaglutide content effectively mimics GLP-1, a naturally occurring incretin hormone that regulates appetite and food intake. This mechanism works primarily through your brain's appetite centres, specifically the hypothalamus, where it may reduce hunger signals and enhance satiety after smaller meal portions. The 1.7mg dose represents a therapeutic level where many patients notice significant appetite modulation compared to earlier escalation stages. As a GLP-1 receptor agonist, Wegovy also slows gastric emptying, contributing to prolonged feelings of fullness between meals. This physiological approach explains why Wegovy must be used alongside a reduced-calorie diet and increased physical activity—the medication supports behavioural changes rather than replacing them.
Ordering Process for Wegovy 1.7mg vs Mounjaro
Both Wegovy 1.7mg and Mounjaro require identical ordering processes through our platform, beginning with a comprehensive 3-minute clinical assessment covering your medical history, current medications, and weight management goals. Our qualified prescribers review applications within 3 working days (or 24 hours with express service), ensuring each prescription meets MHRA guidelines for safe prescribing. Once approved, both medications dispatch via next-day cold-chain delivery, maintaining the required 2-8°C temperature throughout transit to preserve medication integrity. The assessment covers BMI requirements (≥30, or ≥27 with weight-related comorbidities), previous weight management attempts, and any contraindications specific to GLP-1 or GLP-1/GIP medications. This thorough process ensures you receive the most appropriate prescription-only medicine for your circumstances whilst meeting all regulatory requirements under our GPhC registration (#9012878).
Storage and Practical Considerations for Wegovy 1.7mg Price
Wegovy's storage requirements directly impact its practical value, especially at the 1.7mg maintenance-approach stage where treatment continuity becomes crucial. Once removed from refrigeration (2-8°C), Wegovy remains stable for up to 6 weeks at room temperature below 30°C, compared to Mounjaro's 21-day room temperature limit. This storage advantage proves particularly valuable for frequent travelers or those with unpredictable schedules approaching long-term maintenance. The FlexTouch pen design ensures accurate 1.7mg dosing with clear dose confirmation, whilst the weekly injection schedule maintains consistent therapeutic levels. Proper storage directly affects medication efficacy and safety, making these practical considerations essential factors in your long-term treatment planning and overall cost-effectiveness evaluation.
Wegovy 1.7mg Price vs Mounjaro: Escalation Timeline Comparison
The Wegovy 1.7mg price represents week 13-16 of a five-dose escalation schedule, positioning you just four weeks from 2.4mg maintenance dosing. In contrast, Mounjaro follows a six-dose escalation over 20 weeks, meaning equivalent timing places you at their 7.5mg dose level. This timing difference affects treatment planning and budgeting, as Wegovy patients reach maintenance dosing four weeks earlier than Mounjaro patients.
Understanding these escalation differences helps explain pricing structures and treatment duration planning. Wegovy's more rapid progression to maintenance may appeal to those seeking quicker therapeutic optimization, whilst Mounjaro's extended escalation might suit patients preferring gradual dose increases. Both approaches reflect evidence-based protocols designed to minimize side effects whilst achieving optimal therapeutic response through their respective mechanisms of action.
Making Your Choice: Wegovy 1.7mg Price and Beyond
At the 1.7mg stage, treatment decisions extend beyond immediate pricing to long-term maintenance considerations, storage practicalities, and individual response patterns. Both Wegovy and Mounjaro represent evidence-based approaches to weight management, each with distinct mechanisms, dosing schedules, and practical considerations that affect overall treatment experience. Your prescriber can evaluate your individual response to date, lifestyle factors, and clinical profile to recommend the most suitable option moving forward.
EverydayMeds supplies both medications through our GPhC-registered pharmacy, ensuring you can access either option based on clinical need rather than supply limitations. Whether continuing with Wegovy 1.7mg toward 2.4mg maintenance or considering Mounjaro's dual-hormone approach, our clinical team supports evidence-based prescribing decisions that align with NICE guidelines and MHRA licensing requirements. Both medications require ongoing commitment to dietary and lifestyle modifications for optimal outcomes, making the choice a collaborative decision between you and your healthcare provider.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
